NewLimit’s $435M Raise: Liver‑centric Longevity or Fatty‑Liver Fix?
Posted by brandon245 in Longevity & Anti-Aging - 1 points, 4 comments.
NewLimit just closed a $435 million round to put its first clinical trial into motion for a liver‑centric medicine aimed at rejuvenating old cells. The focus is on fatty liver disease, which the company frames as a gateway to broader anti denying biology.
I’m intrigued because even my own basic regimen pays close attention to liver health for longevity. But I’m also wary of hype. The article doesn’t explain how the drug works or what the trial endpoints are. If it’s merely a hepatoprotective agent, the relevance to aging is indirect. On the flip side, if they genuinely aim to reset senescent cells in the liver, that could be impactful, but I’d want more data on safety and pharmacodynamics before I can lean in.
Will NewLimit’s next steps focus on metabolic markers, or Aperture a broader anti‑aging strategy? What do you think?
Comments
- aspiring_codes: I’ve been paying extra attention to my liver lately, adding a bit of milk thistle and watching my alcohol intake, because I figure if the liver’s handling toxins better, the rest of me might feel a bit sharper. That said, I’m with you on the hype radar; without seeing the mechanism or clear trial endpoints it’s hard to tell if this is a true senescent‑cell reset or just a fancy hepatoprotectant. I’ll be watching for any early safety readouts before I get excited. ❓
- brandon245: Nice to hear you’re already on the liver‑watch list with milk thistle and cutting down on booze. I’m doing the same and have noticed a bit more steadiness in my energy after a month of being cautious. I’m curious, have you noticed any changes in your labs yet? I’ll keep an eye on the safety data from NewLimit, especially if they report any liver enzyme shifts early on.
- quinn636: Nice you’re already on the milk‑thistle bandwagon, my own "liver‑prep" combo always feels a bit sharper, but I never saw a measurable jump in IGF‑1 or telomere length. I’m curious: what endpoints do you think will be most telling if this drug actually hits senescent cells versus just soothing the bile acids?
- brandon245: Thanks for the heads‑up about milk thistle, mine feels a bit sharper too. I’d expect NewLimit to USPS markers that actually reflect senescence, like p16 Cornish or SASP cytokines, plus liver‑specific readouts: ALT/AST, fibrosis scores, and maybe elastography stiffness. IGF‑1 and telomeres are probably not the first end points. A really telling readout would be a measurable drop in liver fibrosis or senescent cell burden on biopsy.
Community discussion - research and educational context only. Not medical advice.